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DOI 10.1016/j.chembiol.2012.01.009The concept of drug discovery often
brings images of wet chemistry experi-
mentation, large-scale automation, and
biological assays—processes usually
carried out in laboratory environments.
But within the past few years, some
companies are going virtual with their
drug discovery efforts, taking advantage
of the leaps in computing power and tech-
nology available through the cloud.
To meet the need of pharmaceutical
and biotech companies, and a much
larger cast of supporting and collabo-
rating partners, a few commercial compa-
nies are now providing cloud-based drug
discovery software services. The goal is
to increase the power of collaboration
while maintaining the highest levels of
security, at the same time lowering the‘‘In a cloud-based world there are essentially no barriers.’’—
Barry Bunin, CEO, Collaborative Drug Discoveryneed for sometimes voluminous internal
computer power and IT overhead.
To date, two companies are proving
that the sky is no longer the limit for drug
discovery. Collaborative Drug Discovery
(CDD) of Burlingame, California, and
SCYNEXIS, based in Research Triangle
Park, North Carolina, have emerged as
the leaders of these services offering
private, secure, cloud-based drug
discovery software platforms. Both high-
light the collaborative nature of their prod-
ucts and the reduced costs provided by
the barrier-free virtual world of cloud
computing—and both are finding users
interested in pursuing drug discovery in
a hosted colocation service in the cloud.
Collaborative Drug Discovery
Collaborative Drug Discovery’s (CDD)
software has literally been in the cloud
since the company was founded over
7 years ago and is probably the earliest
entry into the field. As its name implies,
collaboration is the focal point of the soft-
ware. ‘‘From a collaborations perspective,
to be maximally efficient for drugdiscovery, you want to collaborate with
whoever has the best in the world
complementary capabilities. In a cloud-
based world, there are essentially no
barriers,’’ says Barry Bunin, CDD CEO
and founder. ‘‘Users can work with
whoever has the best complementary
skills, technology, or services and control
the intellectual property as needed,
removing much of the technological and
communication friction of traditional
collaborations.’’ With cloud-based ser-
vices, anyone with an internet connection
and the proper security codes can fully
participate in the drug discovery effort.
CDD’s product is not just a data facili-
tator or storage solution. It also includes
proprietary software developed internally
to expedite and simplify drug discoveryprojects. CDD has developed tools that
recognize chemistry structures (which
represent potential composition patents)
and bioactivity data (representing utility
patents) —the core of chemical registra-
tion and structure-activity relationships
(SAR).
‘‘We have put a lot of work into the
design and ease-of-use of the software,
so it is easy to use,’’ says Bunin, who
conceived of the CDD business model
while an ‘‘entrepreneur in residence’’ at
Eli Lilly working on identifying innovative
business models for drug discovery.
He had previously founded another
company, Libraria (now Eidogen-Ser-
tanty), where he built the first gene
family-wide SAR and combinatorial reac-
tion databases. While at Lilly, Bunin found
the support and seed funding to demon-
strate the efficiency of cloud-based
management and distributed drug
discovery and conceived of the CDD
prototype. ‘‘We have developed a very
useful software platform that adds a lot
of value. It is not just putting data in the
cloud. It is a whole series of tools thatChemistry & Biology 19, January 27, 20make the data meaningful,’’ he adds.
These tools make it easy to work with bio-
logical information such as IC50, the Hill
slope, and Z prime statistics, and on the
chemistry side provide a similar ability to
view molecules in 3D.
SCYNEXIS
SCYNEXIS has successfully collaborated
withmost of the world’s large pharmaceu-
tical companies through its cloud-based
discovery information software system
called Hit Explorer Operating System
(HEOS).Originally formedasadrugdiscov-
ery service organization, SCYNEXIS saw
the need in its own business model for
a software tool toexpeditecommunication
with its clients. ‘‘We needed to find a way
to best communicate and exchange
proprietary information with our cus-
tomers,’’ says Terry Marquardt, Executive
Director, Market Development at
SCYNEXIS. Toward that end, SCYNEXIS
started developing HEOS in 2001.
The company hired former Rhone-Pou-
lenc IT Director Fredric Bost to lead the
HEOS development effort. ‘‘SCYNEXIS
developed HEOS as a cloud-based appli-
cation to address the growing new para-
digm in drug discovery that increasingly
involves collaboration between different
companies and organizations,’’ explains
Bost. ‘‘It enables geographically-dis-
persed scientists – not only from different
departments, but also different companies
with different processes and cultures – to
collaborate together and exchange data
and still function as a team.’’
HEOS started as a tool to help all
collaborating partners exchange data
without fouling each other’s central data-
bases. But about four years ago,
SCYNEXIS began receiving requests
from non-CROclients for licensing access
to its HEOS software package. At that
time, the company expanded its business
model to include the HEOS software as
a stand-alone service. ‘‘Since it has been
available as a cloud-based service, it
offers extreme flexibility to everyone,’’
says Marquardt. Projects are easily12 ª2012 Elsevier Ltd All rights reserved 1
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exchange based on user security
settings. He adds, ‘‘This makes it very
easy for our customers to organize
several different projects without having
to upload all the information repeatedly.
The whole process is just so simple.’’
Like CDD, SCYNEXIS’ services go
beyond simple data storage and sharing.
They, too, have developed a proprietary
system to help scientists work with chem-
istry and biology information, and they
have embedded popular drug discovery
pharma tools into HEOS—well-known
tools like Accelrys’s Pipeline Pilot and
TIBCO’s Spotfire—that are easily recog-
nized industry standards. Users can run
Pipeline Pilot protocols on top of data
captured in the cloud and run Spotfire
lead optimization on the data from a web
window. To maximize HEOS’ availability,
SCYNEXIS formed a marketing agree-
ment with Accelyrs to market the service.
When SCYNEXIS first started offering
its HEOS software, most of the projects
involved big numbers from data-heavy
efforts including combinatorial chemistry,
large chemical libraries, and high-
throughput screening (HTS) campaigns,
but the company finds that over the past
couple of years, clients are reaching for
HEOS more for lead optimization and
preclinical work. ‘‘Now we can easily
capture andmanage evenmore biological
and chemical data, all information that is
relevant for a drug discovery effort,’’
adds Bost.
Diverse User Base
Both CDD and SCYNEXIS find that
customers come in two general varie-
ties—the large company or collaboration
interested in expediting drug discovery
among many parties and the relatively
smaller academic laboratory or biotech
company who rely on cloud-based2 Chemistry & Biology 19, January 27, 2012 ªservices to handle all their drug discovery
data and informatics. But within collabo-
ration, the size and mission of the partici-
pants can vary widely from a remote field
office in a disease-endemic region to
a professor’s research laboratory half
a world away to the global headquarters
of a major pharmaceutical company.
Projects range from a simple database
that is used once to companies who
have signed on for years to have all their
data in the cloud. Scaling collaborations
becomes easier to facilitate because one
does not have to create multiple data-
bases that need to be uploaded multiple
time. Data can be tagged, much like in
Flickr for photographs, and consequently
be available for multiple projects. ‘‘Having
the service in the cloud means that it is
much easier to scale multiple collabora-
tions with finite headcounts, since you
only upload your molecules and libraries
once,’’ says Bunin.
Neglected Diseases
Because of their success working with
a varied customer base, SCYNEXIS and
CDD have both successfully participated
in drug discovery efforts involving ne-
glected diseases—multiparticipant proj-
ects that necessitated the use of a
cloud-based product. ‘‘We found that
working in the cloud helped our clients
with researchers over quite a wide global
distribution, including regions of the world
where neglected diseases are rampant,’’
says Bost, who recently cowrote a paper
about the solutions offered by cloud-
based informatics services in neglected
disease collaborations (Bost et al., 2010).
A cloud-based architecture allows
researchers in remote areas with some-
times limited technological resources to
be full participants in the research project.
‘‘All they have to have is access to the
Internet and the proper security codes,’’2012 Elsevier Ltd All rights reservedadds Bost. This avoids the requirement
for software downloads every few weeks
to all participating computers, and it
ensures that users in various working
environments—companies, academia,
and public health—all participate fully in
the projects. The software acts as the
glue for bringing together all the various
types of researchers and organizations.
SCYNEXIS is going another step
beyond a computer connection to make
its services available on mobile devices.
One can download the HEOS iPhone
application to stay on top of ongoing
projects.Secure Environments
Data security and privacy are central to
the success of these cloud-based tools.
‘‘One can easily make your microscope
or telescope as small or as large as you
want to in terms of permissions to main-
tain security and maximally mine the
data,’’ says CDD’s Bunin. CDD cites its
100% security record over its history
and 26,000 customer logins as a
testament to its security and increasing
customer base. Similarly, SCYNEXIS
claims a faultless HEOS security history.
‘‘We’ve worked with most of the top ten
pharma companies that included use of
HEOS as part of the project,’’ says Mar-
quardt. ‘‘We’ve completed many projects
with these companies using real, confi-
dential data and information and have
never had a security or data breach in
the cloud environment.’’REFERENCE
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